Noxopharm Limited (ASX:NOX), a clinical-stage Australian biotech company, disclosed that all six resolutions put to shareholders at its Annual General Meeting held on 17 November 2026 were passed by poll, including approval to issue shares to three directors in lieu of accrued fees.
Key Points
- All six resolutions were decided by poll and carried at the AGM held on 17 November 2026.
- Resolution 1, the Adoption of the Remuneration Report, passed with 99.86% of poll votes in favour.
- Resolution 2, the re-election of Mr Frederick Bart as Director, passed with 99.93% of poll votes in favour.
- Resolutions 4, 5 and 6 approved the issuance of shares to Fred Bart, Snowy Plains Pty Ltd (an entity controlled by Boris Patkin), and Shanti Capital Pty Ltd (an entity controlled by Peter Marks), each in lieu of accrued directors' fees.
- Resolution 3, approving the future issue of securities under ASX Listing Rule 7.1A, passed with 99.92% of poll votes in favour.
Remuneration Report and Director Re-election Results
At the AGM, the Adoption of the Remuneration Report under Resolution 1 received 58,869,189 votes in favour, representing 99.86% of poll votes cast, with 84,492 votes against. The filing stated the resolution passed with an excess of 75% voted in favour. Resolution 2, concerning the re-election of Mr Frederick Bart as Director, received 66,057,250 votes in favour, equating to 99.93% of poll votes cast, with 45,082 votes against and 1,958,762 abstentions recorded.
Share Issuance Approvals for Directors in Lieu of Fees
Three resolutions were passed approving the issuance of shares to directors in lieu of accrued directors' fees. Resolution 4, covering the approval to issue shares to Fred Bart, passed with 60,423,889 votes in favour at 99.79%, with 124,192 votes against. Resolution 5, covering Snowy Plains Pty Ltd, an entity controlled by Boris Patkin, passed with 67,281,020 votes in favour at 99.80%, with 132,374 votes against. Resolution 6, covering Shanti Capital Pty Ltd, an entity controlled by Peter Marks, passed with 67,011,020 votes in favour at 99.80%, with 132,374 votes against.
ASX Listing Rule 7.1A Securities Approval
Resolution 3, seeking shareholder approval for the future issue of securities under ASX Listing Rule 7.1A, was also carried by poll. The resolution received 67,937,059 votes in favour, representing 99.92% of poll votes cast, with 54,435 votes against and 69,600 abstentions recorded. Noxopharm is described in the filing as a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer, with its lead clinical asset SOF-SKN being developed for cutaneous lupus erythematosus.




Please wait processing your request...